SAN DIEGO & BOSTON & BILBAO, Spain–(BUSINESS WIRE)–Artis BioSolutions (“Artis”), a San Diego-based advanced-therapies development and manufacturing company, today announced that it has entered into a definitive agreement to acquire Syngoi Technologies (“Syngoi”), a Spanish biotechnology company pioneering novel enzymatic approaches for manufacturing synthetic DNA technologies. The acquisition will advance Artis’ strategy of building a differentiated platform to accelerate gene-to-drug discove
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
